Status:
COMPLETED
Topical Cetirizine in Androgenetic Alopecia in Females
Lead Sponsor:
Cairo University
Conditions:
Androgenetic Alopecia
Eligibility:
FEMALE
20-50 years
Phase:
PHASE2
PHASE3
Brief Summary
Cetirizine is a safe and selective, second-generation histamine H1 receptor antagonist, widely used in daily practice. A study showed that cetirizine causes a significant reduction in both the inflamm...
Detailed Description
Androgenetic alopecia (AGA) is the most common form of alopecia in men and women. It is a hereditary, androgen-dependent, progressive thinning of scalp hair that follows a defined pattern. The disease...
Eligibility Criteria
Inclusion
- Females with androgenetic alopecia of age 20-50 years.
- Patients experiencing active hair loss within the last 12 months.
- Sinclair scale 2, 3 and 4.
- Patients willing to continue their current regimen of vitamins and nutritional supplements and not start any new vitamins or nutritional supplements for the duration of the study.
- Patients willing to use a mild non-medicated shampoo and conditioner for the duration of the study.
- Patients who did not receive topical or systemic treatment for androgenetic alopecia or prostaglandins in the last 6 months.
Exclusion
- 1\. Patients with a chronic dermatological condition (eczema, psoriasis, infection, etc) of the scalp other than FPHL.
- 2\. Subjects who had hair transplants, scalp reduction, current hair weave or tattooing in the target area, which makes it difficult to perform hair count assessment.
- 3\. Subjects who received radiation therapy to the scalp, or has had chemotherapy in the past year.
- 4\. Subjects who have a known underlying medical problem that could influence hair growth such as HIV infection, connective tissue disease, a thyroid condition, inflammatory bowel disease or other medical conditions, at the discretion of the investigator.
- 5\. Subjects with clinical diagnosis of alopecia areata or other non-AGA forms of alopecia.
- 6\. Pregnant or lactating females or planning to become pregnant for the duration of the study.
- 7\. Patients with severe cardiovascular disease, uncontrolled or untreated hypertension, arrythmia or clinically relevant hypotension.
- 8\. Subjects with hair loss for greater than 5 years, as medical therapy is unlikely to have much effect at restoring hair follicles inactive for that long of a period.
- 9\. The subject has known hypersensitivity or previous allergic reaction to any of the active or inactive components of the test articles.
- 10\. Patients using any medications that potentially cause drug-induced hair loss (e.g., depotestosterone, haloperidol, methotrexate, methylprednisolone, prednisone, testosterone, divalproex sodium) within the last 3 months.
Key Trial Info
Start Date :
July 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2021
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT04481412
Start Date
July 25 2020
End Date
November 30 2021
Last Update
February 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Al-Kasr Al-Ainy outpatient dermatology clinic
Cairo, ِAl-Kasr Al-Ainy, Egypt, 11559